

MNTL

Tema Neuroscience and Mental Health ETF

Analyst Report

MNTL is actively managed, concentrating on companies engaged in addressing disorders of the central nervous system and mental health worldwide. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.

ESG Themes and Scores

6.33/10

ESG Rate

46.5%

Global Percentile

39.2%

Peer Percentile

Performance Data

	MNTL	ETF Database Category Average	Factset Segment Average
1 Month	3.84%	0.06%	3.23%
3 Month	1.95%	1.73%	6.56%
YTD Return	-4.48%	-1.36%	5.50%
1 Year Return	-11.62%	-6.97%	0.36%
3 Year Return	N/A	-0.53%	-2.05%
5 Year Return	N/A	-0.12%	0.00%

Top 5 Holdings

Symbol	Holding	% Assets
VRTX	Vertex Pharmaceuticals Incorporated	10.45%
REGN	Regeneron Pharmaceuticals, Inc.	8.00%
ALNY	Alnylam Pharmaceuticals, Inc	6.53%
NBIX	Neurocrine Biosciences, Inc.	5.18%
ARGX	argenx SE Sponsored ADR	5.17%

Vitals

Issuer	Dawn Global Topco Ltd.
Brand	Tema
Structure	ETF
Expense Ratio	0.75%
Inception	Jan 22, 2024
Index Tracked	N/A

ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Multi-Cap
Asset Class Style	Growth
Region (General)	Global
Region (Specific)	Broad

FactSet Classifications

Segment	Equity: Global Pharma, Biotech & Life Sciences
Category	Sector
Focus	Health Care
Niche	Pharma, Biotech & Life Sciences
Strategy	Active
Weighting	Proprietary

